Nebulized therapies for childhood pulmonary hypertension: An in vitro model.
Published: 2006
Language: eng
Number of pages: 133
ISBN-13: 9780494213186
Description: Sildenafil, tezosentan and prostacyclin reduce vascular pressures in pulmonary hypertension, but may vasodilate the systemic circulation. Nebulized vasodilators allow targeted drug delivery with high local drug concentrations, less systemic hypotension and better ventilation-perfusion matching. We hypothesized that pulmonary deposition would vary with device type and drug, affecting drug dose delivered. Lung deposition was estimated by in vitro characterization of drug output and particle size distribution of nebulizers using helium-neon laser diffraction techniques. Drug output from the eFlow device was greatest and for the Pari LC Star increased with inspiratory flow. Estimated pulmonary deposition (mean, 95%CI) was 8.1 (7.2, 9.0) % of the initial drug charge for the Hudson Updraft II, 6.4 (5.8, 7.0) % for the Whisperjet, 33.0 (28.3, 37.9) % for the Pari LC Star and 56.8 (40.2, 73.4) for eFlow. All three drugs could be nebulized, but expected pulmonary deposition varied depending on the delivery device and drug.
Notes: Source: Masters Abstracts International, Volume: 45-03, page: 1473.

Thesis (M.Sc.)--University of Toronto, 2006.

Electronic version licensed for access by U. of T. users.

ROBARTS MICROTEXT copy on microfiche.